Non-invasive Glucose Monitoring Devices Market to Reach US$ 60.71 Million by 2033 as Wearable Innovation, Needle-Free Monitoring Demand, and AI-Driven Sensor Platforms Advance Toward Commercial Validation

May 3, 2026 - The global non-invasive glucose monitoring devices market reached US$ 29.53 million in 2023, rose to US$ 31.57 million in 2024, and is projected to reach US$ 60.71 million by 2033, growing at a CAGR of 7.5% during 2025-2033. That implies an incremental revenue opportunity of roughly US$ 29.14 million between 2024 and 2033. The category remains small compared with the broader glucose monitoring industry, but it is strategically important because it targets one of diabetes care's most persistent frictions: the burden of finger sticks and sensor insertions. Demand is being shaped by a clear patient need for painless, convenient, and more sustainable glucose tracking across diabetes and prediabetes management. At the same time, the commercial bar remains high, as the U.S. FDA has warned consumers not to rely on unauthorized smartwatches or smart rings claiming to measure blood glucose, underlining how strongly the market still depends on credible validation and regulatory discipline.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/non-invasive-glucose-monitoring-devices-market?kailas

The market is gaining momentum because technology developers are moving from concept claims toward more structured real-world validation, prototype demonstrations, and platform refinement. Know Labs continues to position its KnowU program around an eventual FDA-cleared non-invasive monitor and says it holds more than 270 patents issued, pending, and in process around its platform. Actxa has pushed a different route, combining wearable PPG sensing with AI models to deliver non-invasive glucose evaluation through everyday devices, while Sensura has shown both handheld and wearable prototype platforms for non-invasive glucose insights. The commercial interpretation is important: this market is no longer only a research story. It is becoming a contest between competing technical approaches such as optical, electromagnetic, and AI-enabled estimation models, with the winners likely to be those that can prove repeatability, usability, and medical relevance under real operating conditions.

Recent Developments

1. In March 2026, Afon Technology said its Glucowear device achieved about 75% overall accuracy in distinguishing between normal and elevated blood glucose levels in its first real-world trial and stated that it would present progress at ATTD 2026. This matters because the market needs more than laboratory optimism. It needs evidence that non-invasive systems can operate outside tightly controlled test settings and still produce clinically meaningful signals.

2. In January 2026, Actxa announced significant enhancements to its BGEM technology, describing it as a clinically backed, non-invasive, AI-driven blood glucose evaluation and monitoring platform. The company also introduced BGEM Glucose Range, a one-minute measurement capability designed for wearable integration. This is commercially relevant because it broadens the field beyond dedicated medical hardware and into wearable-enabled glucose awareness models that may appeal to metabolic wellness and prediabetes monitoring use cases.

3. In January 2026, Sensura said it would showcase a non-invasive health monitoring platform at CES 2026, including both a handheld glucose spot-check device and a wearable designed for continuous glucose trend monitoring. The significance lies in format strategy. Companies are no longer developing only one rigid product form. They are testing both clinical-style and consumer-style designs to improve adherence and expand addressable use cases.

4. In December 2025, Afon Technology won the Innovation Award at the MediWales Innovation Awards 2025 for its Glucowear platform and highlighted prior testing with the NHS, Profil in Germany, and the Joint Clinical Research Facility in Swansea. While an award is not regulatory clearance, it matters because it reflects growing visibility and external validation for one of the few companies openly positioning itself around a real-time, needle-free CGM ambition.

Segment Analysis

By product type, wearable devices are emerging as the leading commercial segment because the strongest patient demand is tied to continuous or near-continuous monitoring without recurring pain or manual testing burden. Handheld and non-wearable systems still have value in spot checks and clinical screening, but the real economic upside sits in devices that can fit naturally into daily life and support recurring engagement. Afon's wrist-worn Glucowear, Sensura's wearable prototype, and Know Labs' KnowU concept all reinforce the same point: the market's central promise is not simply non-invasive measurement. It is non-invasive measurement that people can realistically live with every day.

By technology, optical and electromagnetic approaches are the most strategically important segments, although the market remains technically fragmented. DiaMonTech's published work is based on infrared photothermal methods, while Know Labs uses radiofrequency dielectric spectroscopy and Afon uses ultra-low-power microwave signals. In business terms, this matters because no single technical pathway has yet emerged as the clear commercial winner. The market is still in a platform-selection phase, where the eventual leaders will likely be those that can balance accuracy, device comfort, calibration burden, manufacturing feasibility, and regulatory acceptance.

Regional Analysis

The United States remains the most commercially important market because it combines high diabetes prevalence, strong adoption of glucose monitoring technologies, and the deepest ecosystem of device developers, payers, and regulatory scrutiny. The FDA's safety communication warning consumers against unauthorized smartwatches and smart rings that claim to measure blood glucose is a critical market signal. It shows that the demand for needle-free monitoring is real, but it also makes clear that market entry will depend on strong evidence and formal authorization rather than consumer-electronics hype. Structurally, the U.S. is likely to remain the leading market for commercialization because it has the strongest mix of patient demand and regulatory clarity.

Japan is strategically important because of its large diabetes burden and strong medical device ecosystem. Japan's Ministry of Health, Labour and Welfare said in the results of its 2024 National Health and Nutrition Survey that the number of people strongly suspected of having diabetes is estimated at about 11 million and continues to increase. That is not a direct market-size figure for non-invasive glucose devices, but it is a meaningful structural demand indicator. In practical terms, Japan offers an attractive environment for future adoption because high diabetes prevalence combines with a quality-sensitive healthcare market that values reliable monitoring technologies.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-invasive-glucose-monitoring-devices-market?kailas

Company Profiles

Know Labs, Inc. is one of the purest strategic plays in the category. The company says it is focused on bringing the world's first FDA-cleared non-invasive blood glucose monitor to market and states that it has more than 270 patents issued, pending, and in process around its technology. Know Labs matters commercially because it is building specifically for the core promise of the market rather than adapting from adjacent glucose-monitoring categories.

Nemaura Medical Inc. remains highly relevant because it is one of the few companies with a long-running dedicated non-invasive glucose program through sugarBEAT. Nemaura has described sugarBEAT as a non-invasive and flexible continuous glucose monitor and has positioned it around both diabetes and prediabetes use cases. The company matters because it represents one of the earliest serious attempts to commercialize a wearable non-invasive CGM pathway.

Abbott Laboratories is commercially significant even though its mainstream glucose-monitoring strength remains in minimally invasive systems. Abbott reported US$ 44.3 billion in full-year 2025 sales, and its FreeStyle Libre franchise continues to shape user expectations around real-time glucose data. Abbott matters in this market because non-invasive entrants are not competing in a vacuum. They are competing against a high-performance incumbent standard that already has scale, reimbursement traction, and strong brand trust.

Dexcom, Inc. is another important benchmark player. Dexcom reported approximately US$ 4.66 billion in fiscal 2025 revenue and remains one of the best-known companies in continuous glucose monitoring. Its relevance to the non-invasive segment is strategic: any successful needle-free platform will need to match or at least approach the reliability, clinical utility, and user confidence that companies like Dexcom have already built in the wider CGM market.

Analyst View

The strongest revenue pools in this market are likely to form where comfort, continuous use, and clinically useful trend visibility overlap. That makes wearable devices, type 2 diabetes and prediabetes applications, and home care settings the most commercially attractive areas over the medium term. The biggest opportunity is not just in replacing finger sticks. It is in expanding the monitored population to include people who currently avoid glucose tracking because invasive methods are inconvenient, painful, or too disruptive for daily use.

Competition is intensifying around proof, not promise. The likely winners will be the companies that can show real-world accuracy, user-friendly design, manufacturable hardware, and credible regulatory progress at the same time. In this market, the value will not go to the loudest claims. It will go to the developers that make non-invasive glucose monitoring dependable enough to be used with confidence in everyday diabetes management.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.